R. Philippe

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

J. McCaffrey, F. Calabrò, A. Thiery-Vuillemin, 2022, Annals of Oncology.